Atomoxetine

Primary Uses

Atomoxetine is primarily prescribed to manage the symptoms of attention deficit hyperactivity disorder (ADHD). It is approved for use in children aged 6 years and older, as well as in adults.

This medication works by affecting certain chemicals in the brain to help improve specific behaviors, including:

• Increasing the ability to pay attention and stay focused on tasks.
• Decreasing impulsive behaviors.
• Reducing restlessness or hyperactivity.

Comprehensive Treatment

While atomoxetine can help manage ADHD symptoms, it is typically used as part of a total treatment program. This program may also include other types of support, such as:

• Psychological counseling.
• Educational therapy.
• Social therapy.

Unlike many other medications used for ADHD, atomoxetine is not a stimulant. This makes it an alternative for individuals who cannot take stimulants or for whom stimulants have not been effective.

Mechanism of Action

Atomoxetine belongs to a class of medications known as selective norepinephrine reuptake inhibitors (SNRIs). While the exact way it works to treat Attention-Deficit/Hyperactivity Disorder (ADHD) is not fully understood, it is believed to work by affecting how the brain uses a specific chemical messenger called norepinephrine.

How It Affects the Brain

Norepinephrine is a neurotransmitter that plays a key role in regulating attention, impulsivity, and activity levels. In individuals with ADHD, the balance of these chemicals may be disrupted. Atomoxetine works by:

• Blocking reuptake: It prevents the brain from quickly reabsorbing norepinephrine after it has been released.
• Increasing availability: By blocking this reabsorption, the medication increases the amount of norepinephrine available to send signals between nerve cells.

Therapeutic Effects

By maintaining higher levels of norepinephrine in certain parts of the brain, atomoxetine helps to:

• Improve the ability to pay attention and stay focused.
• Decrease impulsive behaviors.
• Reduce hyperactivity.

Unlike many other medications used for ADHD, atomoxetine is not a stimulant. Because of how it interacts with brain chemistry, it may take several weeks of consistent use before the full therapeutic benefits are noticed.

Common Side Effects

Many people taking atomoxetine experience mild side effects. These often include:

• Nausea, vomiting, or heartburn
• Stomach pain, gas, or constipation
• Loss of appetite and weight loss
• Dry mouth
• Dizziness or tiredness
• Mood swings or irritability
• Changes in sexual desire or performance
• Painful or difficult urination
• Menstrual cycle changes

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Signs of liver problems, such as yellowing of the skin or eyes, dark urine, or pain in the upper right stomach area
• Cardiovascular issues, including chest pain, shortness of breath, or a fast or irregular heartbeat
• Psychiatric symptoms, such as hallucinations, mania, aggression, or new or worsening anxiety
• Suicidal thoughts or behaviors, particularly in children and teenagers
• Seizures
• Fainting or extreme dizziness
• Numbness or weakness in the arms or legs
• A painful or prolonged erection lasting several hours
• Signs of an allergic reaction, such as hives, rash, itching, or swelling of the face, throat, or tongue

Suicidal Ideation

Atomoxetine may increase the risk of suicidal thoughts or actions in children and adolescents. This risk is highest during the first few months of treatment or when the dose is changed. Caregivers are advised to monitor for changes in behavior, worsening depression, or signs of self-harm.

Contraindications

This medication is not recommended for individuals with certain medical conditions, including:

• Current or recent use (within 14 days) of monoamine oxidase inhibitors (MAOIs).
• Narrow-angle glaucoma.
• Pheochromocytoma (a type of adrenal gland tumor).
• Severe cardiovascular disorders that could worsen with increases in heart rate or blood pressure.

Cardiovascular Risks

Atomoxetine can increase blood pressure and heart rate. Serious heart-related events, including sudden death, stroke, and heart attack, have been reported in patients with pre-existing structural heart defects or other serious heart problems. Healthcare providers typically assess heart health before starting treatment.

Liver Injury

In rare cases, atomoxetine can cause severe liver injury. Signs of liver problems include yellowing of the skin or eyes (jaundice), dark urine, itching, or tenderness in the upper right side of the abdomen. The medication should be discontinued if liver injury is confirmed.

Psychiatric Symptoms

New or worsening psychiatric symptoms may occur, such as hallucinations, delusional thinking, or mania, even in patients without a prior history of these conditions. It may also trigger aggressive behavior or hostility in some individuals.

Other Precautions

• Priapism: Rare but serious cases of painful or prolonged erections have been reported and require immediate medical attention to prevent permanent damage.
• Urinary Effects: Some patients may experience difficulty starting urination, a weak urine stream, or urinary retention.
• Growth Monitoring: Because atomoxetine may affect growth and weight in children, healthcare providers often monitor height and weight during long-term treatment.

Pregnancy

There is limited information regarding the safety of atomoxetine during pregnancy. While studies in animals have shown some potential for developmental issues when the drug was administered at high doses, there are no adequate and well-controlled studies in humans. Because of this lack of data, atomoxetine is typically only recommended during pregnancy if a healthcare provider determines that the potential benefit to the parent justifies the potential risk to the developing fetus.

Breastfeeding

It is currently unknown whether atomoxetine passes into human breast milk. Because many drugs are excreted in human milk, caution is advised for those who are nursing. The effects of the medication on a breastfeeding infant have not been established.

Consult Your Healthcare Provider

If you are pregnant, planning to become pregnant, or are currently breastfeeding, it is important to discuss the risks and benefits of continuing or starting atomoxetine with your doctor. They can help evaluate your specific situation and determine the safest course of treatment.

Available Forms

Atomoxetine is supplied as a capsule for oral administration. These capsules are intended to be swallowed whole.

• Oral capsule

It is important not to open, crush, or chew the capsules. The powder inside the capsule can be an irritant to the eyes and skin if the capsule is broken.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) first approved atomoxetine in 2002 for the treatment of attention-deficit hyperactivity disorder (ADHD). It is indicated for use in children aged 6 years and older, adolescents, and adults. Unlike many other medications used for ADHD, atomoxetine is classified as a non-stimulant and is not a controlled substance under the Controlled Substances Act.

Boxed Warning

Atomoxetine carries a boxed warning, the FDA’s most serious type of warning, regarding an increased risk of suicidal ideation in children and adolescents. Clinical trials indicated a small but significant risk of suicidal thinking in pediatric patients taking this medication compared to those taking a placebo. Healthcare providers are advised to closely monitor patients starting treatment or changing doses for signs of clinical worsening, suicidality, or unusual changes in behavior.

Safety Communications and Precautions

The FDA has issued safety communications and labeling updates for atomoxetine regarding several serious risks:

• Severe Liver Injury: Post-marketing reports have identified cases of severe liver injury. The FDA recommends discontinuing the medication in patients who develop jaundice or laboratory evidence of liver damage.
• Cardiovascular Effects: The medication can increase blood pressure and heart rate. It should be used with caution in patients with known structural cardiac abnormalities, cardiomyopathy, or serious heart rhythm problems.
• Psychiatric Symptoms: Treatment may emerge or worsen symptoms of psychosis or mania in patients without a prior history of these conditions.

Withdrawal and Dependence

Atomoxetine is classified as a selective norepinephrine reuptake inhibitor (SNRI) rather than a stimulant. Because of this, it has different characteristics regarding withdrawal and dependence compared to many other ADHD medications:

• Low Risk of Abuse: Atomoxetine is not a controlled substance. It does not have a high potential for abuse or physical dependence, and it does not produce the euphoric effects associated with stimulants.
• Lack of Withdrawal Syndrome: Clinical trials have shown no evidence of a specific withdrawal syndrome occurring when the medication is discontinued.
• No Rebound Effect: In studies, patients who stopped taking atomoxetine abruptly did not experience a "rebound" effect, which is a sudden and severe return of ADHD symptoms immediately after stopping a drug.

Even though withdrawal symptoms are unlikely, you should not stop taking atomoxetine without first consulting your healthcare provider. Your doctor will help you determine the best way to end treatment and will monitor you to see if your ADHD symptoms return over time.